(UroToday.com) At this year’s European Society of Medical Oncology (ESMO) 2020 Virtual Congress, following a number of abstracts assessing the role of immunotherapy in advanced urothelial carcinoma, Dr. Kilian Gust provided an invited discussion regarding the future of immunotherapy in this disease with a focus on how to combine and sequence therapies.
(UroToday.com) Despite a number of therapies with proven survival benefit, the prognosis of patients with advanced urothelial carcinoma remains poor. In addition to cytotoxic chemotherapy using a platinum-based regime, the use of checkpoint inhibitors has demonstrated promise. However, long-term responses are rare.
(UroToday.com) Despite similar mechanisms of action, antibodies (such as nivolumab and pembrolizumab) against the T-cell checkpoint PD-1 protein have different safety and efficacy profiles when used in cancer therapy. This is likely due to in part to differences in antibody humanization, sequence differences in complementarity-determining regions, as well as different pharmacokinetics.1 While durable responses are observed in […]
(UroToday.com) Advanced urothelial carcinoma has among the worst prognosis for tumors treated by genitourinary oncologists. Standard of care dictates that patients receive platinum-based induction chemotherapy. However, even with this treatment, rates of recurrence and disease progression are high and overall survival is quite short due to the development of chemotherapy resistance. In the JAVELIN Bladder 100 […]
(UroToday.com) It is well-known that locally advanced and metastatic urothelial carcinoma is an incurable disease with poor overall survival (OS), especially in patients who progress on or after platinum-containing chemotherapy.
(UroToday.com) The QuEST1 trial was designed to rapidly interrogate the safety and efficacy of a combination of immunotherapy regiments and see the activity of immunotherapy in castrate-resistant prostate cancer (CRPC).The analyzed regimen in the presented study (Figure 1) included three factors:
(UroToday.com) Up to 30% of metastatic castration-resistant prostate cancer (mCRPC) men harbor DNA damage repair defects and may benefit from poly-ADP ribose polymerase (PARP) inhibitors after abiraterone/enzalutamide and docetaxel failure. Cabazitaxel was recently shown to improve overall survival in this population,1 though benefit by DNA damage repair status is unknown. At the prostate cancer session during the […]
(UroToday.com) Germline BRCA2 mutations are associated with more aggressive disease and poor clinical outcomes in prostate cancer. Small series have shown that prostate tumors in germline BRCA2 carriers present with more copy number alterations than tumors in non-carriers, including higher frequency of BRCA2 LOH, RB1 loss, and MYC amplification/gain.1 These aberrations may contribute to explaining the poor prognosis […]
(UroToday.com) At the European Society of Medical Oncology – 2020 Virtual Congress (ESMO), Dr. Andrea Alimonti began his talk discussing the 615MO abstract: “Phase 1b/2 study of VERU-111, novel, oral tubulin inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC) who failed an androgen blocking agent”, presented by Dr. Mark Markowski.
San Francisco, CA (UroToday.com) — EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, and Pfizer Inc. announced the publication of detailed results from the Phase III JAVELIN Bladder 100 study online ahead of print in The New England Journal of Medicine. These results were published simultaneously with additional analyses being presented at the […]
